Journal
CANCER LETTERS
Volume 341, Issue 2, Pages 132-138Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2013.08.008
Keywords
PDAC; Molecular imaging; Ultrasonography
Categories
Funding
- National Cancer Institute of the National Institutes of Health [R37-CA-075059]
- Cancer Research UK [16464] Funding Source: researchfish
Ask authors/readers for more resources
Pancreatic ductaladeno carcinoma (PDAC) is a deadly cancer characterized by multiple molecular alterations, the presence of an intense stroma, poor perfusion, and resistance to therapy. In addition to standard imaging techniques, experimental imaging strategies, such as those utilizing molecular probes, nanoparticle-based agents, and tagged antibodies are actively being explored experimentally. It is hoped that advances in these technologies will allow for detecting PDAC at an early stage, and could serve to validate experimental therapies, rapidly identify non-responders, and assist in the design of novel therapeutic strategies tailored to the patient's molecular profile. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available